Genelabs Technologies

Genelabs Technologies

Biotechnology Research 126 employees
Employees
126

Genelabs Technologies Overview

Phone Number
Available in AeroLeads
Website
genelabs.com
Industry
Biotechnology Research
Employees
126
Funding
9.0M
Company Email
Available in AeroLeads
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)

About Genelabs Technologies

Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.

Genelabs Technologies Contact Details

Employees by Management Level

Individual contributor 5 profiles
Director 4 profiles
Executive 2 profiles
Manager 2 profiles
Senior / Lead 2 profiles
Associate / junior 1 profile

Department Contact Coverage

Department Contacts Email Phone
General 9 9 1
Executive 4 4 1

Genelabs Technologies Tech Stack

Data / AI 2 profiles

Compare Similar Companies to Genelabs Technologies